Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)-Reference-Cited by-同舟云学术

Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)

Published:2018-10 Issue:2 Volume:183 Page:235-241
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Krauter Jürgen¹,Fiedler Walter²,Schlenk Richard F.³,Paschka Peter⁴,Thol Felicitas¹,Lübbert Michael⁵,Wattad Mohammed⁶,Verbeek Mareike⁷,Könecke Christian¹,Neuhaus Barbara⁸,Papkalla Armin⁸,Kebenko Maxim²,Janning Melanie²,Döhner Konstanze⁴,Gaidzik Verena I.⁴,Becker Heiko⁵^ORCID,Greil Christine⁵,Reimer Peter⁶,Götze Katharina S.⁷,Döhner Hartmut⁴^ORCID,Ganser Arnold¹,Heuser Michael¹^ORCID

Affiliation:

1. Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation; Hannover Medical School; Hannover Germany

2. Department of Oncology, Haematology and Bone Marrow Transplantation with section Pneumology; Hubertus Wald University Comprehensive Cancer Centre Hamburg; University Medical Centre Hamburg-Eppendorf; Hamburg Germany

3. NCT-Trial Centre; National Centre for Tumour Diseases; Heidelberg Germany

4. Department of Internal Medicine III; University of Ulm; Ulm Germany

5. Department of Haematology-Oncology; Faculty of Medicine Freiburg; University of Freiburg Medical Centre; Freiburg Germany

6. Evangelisches Krankenhaus Essen-Werden; Essen Germany

7. Department of Internal Medicine III; Technical University of Munich; Munich Germany

8. Hannover Clinical Trial Centre; Hannover Medical School; Hannover Germany

Funder

Genzyme

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject